Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesLivin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment
Urologic Oncology: Seminars and Original Investigations, 07/01/09
Liu H-B et al. - In a study to evaluate expression of Livin in bladder cancer, investigate its clinical and prognostic implications, and explore the effect of gene Livin transfection on proliferation and apoptosis in bladder cancer cells, it was determined that Livin may serve as a promising marker to identify the relapse risk in bladder cancer, and targeting Livin could offer a therapeutic benefit in apoptosis-inducing treatment.
Methods- Expression of Livin-α and -β was detected in 48 bladder cancer samples (G1 in 23 cases, G2 in 17, and G3 in 8).
- Of the 48 cases, 17 developed relapse and 15 non-tumor bladder tissues by Western blot and reverse transcription PCR (RT-PCR).
- Livin-α-pcDNA3.1(+) was constructed and transfected into T24, BIU-87, and EJ bladder cancer cells.
- Clone activity of the transfected cells was detected by colony formation analysis.
- MTT was used to determine the cell proliferation assay.
- Flow cytometry and acridine orange staining were used to examine apoptosis.
- Caspase 3 activity assay was also measured.
- Expression of Livin-α, but not -β, was detected in 19 of 48 bladder cancer samples; G1 was 39.13%, G2 and G3 were 41.18% and 37.50%, respectively, which showed no significance, but not in 15 non-tumor bladder tissues.
- Positive rate of Livin-α was significantly higher in relapse tumors (58.82%) than in primary tumors (29.03%).
- By 2 yrs follow-up, relapse rate in Livin-positive pts was 68.42%, and 37.93% in Livin-negative group.
- Difference between the 2 groups was significant.
- Overexpression of Livin-α clearly stimulated cell proliferation and inhibited chemical-induced apoptosis in bladder cancer cells.
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Upfront, randomized, phase II trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma
Cancer, 11/03/09
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study
Clinical Cancer Research, 11/17/09
Sponsor
Article Search
Sponsor
Sponsor